CoChat

GLP-1 Receptor Agonist in Nonobese Patients with Type 2 Diabetes Mellitus and Heart Failure with Preserved Ejection Fraction

Open access
KHADKE, SUMANTH, KUMAR, ASHISH, BHATTI, AMMAR, DANI, SOURBHA S., AL-KINDI, SADEER, NASIR, KHURRAM, VIRANI, SALIM S., UPADHYAY, JAGRITI, GARCIA-BANIGAN, DINAMARIE C., ABRAHAM, SONU, HUSAMI, RAYA, KONG, YIXIN, LABIB, SHERIF, VENESY, DAVID, SHAH, SACHIN, LENIHAN, DANIEL, VADUGANATHAN, MUTHIAH, DESWAL, ANITA, FONAROW, GREGG C., BUTLER, JAVED, NOHRIA, ANJU, KOSIBOROD, MIKHAIL N., GANATRA, SARJU · 2025 · Journal of Cardiac Failure
Cited by 25

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

BACKGROUND Glucagon like peptide-1 receptor agonists (GLP-1RA) promote weight loss and improve heart failure-related symptoms, quality of life, and functional capacity in patients with obesity and heart failure with preserved ejection fraction (HFpEF). However, their clinical effectiveness in non-obese patients with diabetes and HFpEF is understudied. METHODS The TriNetX research network was used to identify adult patients (≥18 years) with type 2 diabetes mellitus (T2DM), Heart failure with preserved ejection fraction ((Left ventricular ejection fraction ≥45%), elevated brain natriuretic peptide (≥150pg/mL) or N-terminal pro-B-type natriuretic peptide(≥450pg/mL) and a body mass index (BMI) <30 kg/m2 on or before August 31, 2022. Patients were divided into two groups based on GLP-1RA use. After propensity score matching, Cox proportional Hazard Ratios (HRs) were used to compare outcomes over a 12-month follow-up period. RESULTS The study included 84,990 patients (n= 42,495 per group, mean age 64 years, 49% females, 65% white). Patients on GLP-1RA were associated with lower incidence of heart failure exacerbation events (HR 0.60, 95% CI 0.58-0.62, p<0.001) and all-cause emergency room visits or hospitalizations (HR 0.67, 95% CI 0.66-0.69, p<0.001) compared to those not on GLP-1RA. Other outcomes including acute myocardial infarction, atrial fibrillation, ischemic stroke, pulmonary hypertension, C-reactive protein ≥5mg/L, acute kidney injury, and the need for renal replacement therapy, were also significantly less frequent in the GLP-1RA group. These associated benefits persisted even among patients on sodium-glucose cotransporter-2 inhibitors (SGLT2i). CONCLUSION GLP-1RA use is associated with improved cardiovascular outcomes in non-obese patients with T2DM and HFpEF and has an associated incremental benefit even among patients on SGLT2i.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cardfail.2024.10.448

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 25

Metadata

Authors
KHADKE, S., KUMAR, A., BHATTI, A., DANI, S. S., AL-KINDI, S., NASIR, K., VIRANI, S. S., UPADHYAY, J., GARCIA-BANIGAN, D. C., ABRAHAM, S., HUSAMI, R., KONG, Y., LABIB, S., VENESY, D., SHAH, S., LENIHAN, D., VADUGANATHAN, M., DESWAL, A., FONAROW, G. C., BUTLER, J., NOHRIA, A., KOSIBOROD, M. N., & GANATRA, S.
Venue
Journal of Cardiac Failure
Publisher
Elsevier BV
Published
2025-07
Volume
31
Issue
7
Pages
989-1001
ISSN
1071-9164 (ISSN-L)
OpenAlex
W4405237049
Cited by
25
References
20
FWCI
6.72
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GLP-1 Receptor Agonist in Nonobese Patients with Type 2 Diabetes Mellitus and Heart Failure with Preserved Ejection Fraction. https://app.cochat.ai/papers/10.1016/j.cardfail.2024.10.448
The paper
KHADKE, S., KUMAR, A., BHATTI, A., DANI, S. S., AL-KINDI, S., NASIR, K., VIRANI, S. S., UPADHYAY, J., GARCIA-BANIGAN, D. C., ABRAHAM, S., HUSAMI, R., KONG, Y., LABIB, S., VENESY, D., SHAH, S., LENIHAN, D., VADUGANATHAN, M., DESWAL, A., FONAROW, G. C., . . . GANATRA, S. (2025). GLP-1 Receptor Agonist in Nonobese Patients with Type 2 Diabetes Mellitus and Heart Failure with Preserved Ejection Fraction. Journal of Cardiac Failure. https://doi.org/10.1016/j.cardfail.2024.10.448

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.